Background and aims Precise predictors are lacking for hepatitis B surface antigen (HBsAg)
clearance under the combination therapy of nucleos (t) ide analogs (NA) and pegylated …

Combination therapy with pegylated interferon (PEG‐IFN) and nucleos (t) ide analogues
(NAs) can enhance hepatitis B surface antigen (HBsAg) clearance. However, the specific …

Abstract Background & Aims The effectiveness and safety of peginterferon alpha (peg‐IFN‐
α) monotherapy in inactive hepatitis B virus (HBV) carriers (IHCs) have not been fully …

The management of hepatitis B virus (HBV) infection now involves regular and appropriate
monitoring of viral activity, disease progression, and treatment response. Traditional HBV …

Background and aims The identification of reliable predictors for hepatitis B surface antigen
(HBsAg) seroclearance remains controversial. We aimed to summarize potential predictors …

Objective The aim of this study was to explore the profile of cytokine changes during the
combination therapy with pegylated interferon alpha (PEG-IFN-α) and its relationship with …

Background Among the advantaged population with clinical cure of chronic hepatitis B,
chronic inactive hepatitis B virus carriers (IHCs) and nucleoside analog-experienced …

Although there are therapeutic advantages for hepatitis B virus (HBV) withpegylated
interferon alpha (peg‐IFNα) treatment compared with nucleos (t) ide analog (NAs) therapy …

Currently, interferon add-on therapy brings hope for clinical cure of chronic hepatitis B
patients with low HBsAg. However, in clinical practice patients with poor responses to their …

Introduction Hepatitis B surface antigen (HBsAg) clearance is the treatment goal for hepatitis
B e antigen (HBeAg)-negative patients with chronic hepatitis B (CHB). However, its rate is …